


"Supermobile Superbugs" International travel and antibiotic resistance

Patrick Harris
Microbiologist, Pathology Queensland; ID Physician PA Hospital



Deaths attributable to AMR every year compared to other major causes of death







Tackling drug-resistant infections globally

Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations

The Review on Antimicrobial Resistance Chaired by Jim O'Neill December 2014







Review on

More than 2 billion people travel long distances each year



~300 million / year travel to areas highly endemic for antibiotic resistance





Global movement of people

- IATA: ~1.45 billion international air travel passengers estimated for 2016
 - ~35% of all international air travel in Asia-Pacific region, set to expand rapidly
- UN Tourism: 348 million international tourists Jan-April 2016
 - ~18 million more than the same period in 2015 (+5.3%)
 - 2016: will be the 7th consecutive year of aboveaverage growth in tourism


Global air passengers by region (% of total flows)




http://www.iata.org, http://www2.unwto.org








Gram-negatives possess multiple mechanisms to resist antibiotics






- Plasmids and resistance
 - ~25% of bacterial genome acquired by Lateral Gene Transfer
 - Allows phenomenal diversity and rapid adaptation
 - >18,000 potential genes in the E. coli "pan-genome" despite there being only ~2000 genes in each cell

"Lateral gene transfer potentially makes *all genes in the microbial biosphere a single, common and shared resource*. In the same way that wars can be won by nations with the greatest industrial capacity, so it is that bacteria can draw on a global resource that can rapidly mobilize and transfer useful genes across physical and phylogenetic distances."

Stokes & Gillings FEMS Microbiol Rev 35 (2011): 790–819

CTX-M: A true global traveller





- Once CTX-M penetrates a specific geographic area it tends to displace TEM / SHV ESBLs
- Frequently seen in successful pandemic clones e.g. ST131 uropathogenic *E. coli*

- "Cefotaximase-Munich" ESBL
- Origins from chromosomal klu beta-lactamase of *Kluyvera*
 - plasmid uptake in common pathogens e.g. E. coli, Salmonella spp
 - May have occurred multiple times
- During 1990s, different reports at the same time of the same enzymes in very distant countries

Microbiology and Molecular Biology Reviews

MERINO Trial: 3GC-R E. coli / K. pneumoniae in BCs






33% bla_{CTX-M-15}
23% bla_{CTX-M-27}
9% bla_{CTX-M-14}
(all belong to
CTX-M-9 lineage)






3rd generation cephalosporin resistant Enterobacteriaceae – urinary isolates



Carbapenem retail sales in selected countries, 2005–2010 (per 1,000 population)




Source: Laxminarayan et al. 2013 (based on IMS MIDAS)


*An IMS grouping of Benin, Burkina Faso, Cameroon, Côte d'Ivoire, Gabon, Guinea, Mali, Republic of the Congo, Senegal, and Togo



Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, $2008-2014^{\frac{1}{12}}$




Antimicrobials Increase Travelers' Risk of Colonization by Extended-Spectrum Betalactamase-Producing *Enterobacteriaceae*








ESBLs; 37% if had diarrhoea and antibiotics






What is happening in Australia?

Resistance in community-onset infections



	Year		
	2008	2010	2012
- Ampicillin %I	353	1.3	1.9
- Ampicillin %R	44.4	43.4	44.3
Cefazolin %R	12.3	15.2	14.3
- Ceftriaxone %NS	2.1	3.2	4.2
— Ciprofloxacin %NS	4.2	5.4	6.9
- Gentamacin %R	3.5	4.2	4.3
- Meropenem %NS	0.1	0.0	0.0






		Year	
	2008	2010	2012
- Cefazolin %R	19.3	17.5	20.0
— Ceftriaxone %NS	4.2	3.6	5.0
— Ciprofloxacin %NS	2.5	2.2	2.8
— Gentamacin %R	2.7	1.9	2.4
- Meropenem %NS	0.0	0.2	0.0

AUSTRALIAN COMMISSION
ON SAFETY AND QUALITY IN HEALTH CARE



Resistance patterns in the Queensland public hospital sector for bacterial isolates from blood culture for species from the family Enterobacterlaceae, 2006 to June 2014



Isolates were the first isolate per specimen per person per year. The upper panels show the percentage of nonsusceptible isolates for each antimicrobial. The lower panels show resistance to ceftriaxone, which is mostly attributable to production of extended-spectrum β-lactamase (ESBL), ESBL was not determined for Enterobacter species,

Source: OrgTRx, Queensland Health²

AUSTRALIAN COMMISSION ON SAFETY AND QUALITY IN HEALTH CARE




Enterobacter cloacae and E. aerogenes


May 2016: retrieval from an overseas hospital

Severe burns – day 4 of admission (under contact precautions from admission)



Polymicrobial bloodstream infection, including carbapenem-resistant *A. baumannii* (CRAB): susceptible only to colistin (MIC 0.125), tigecycline (MIC=2) and doxycycline (MIC=2)





Acknowledgements



p.harris@uq.edu.au @padstamundo










Metro South Hospital and Health Service

UQCCR / SCMB / ACE

- Scott Beatson
- Mark Schembri
- Leah Roberts
- Brian Forde
- David Paterson





Pathology Queensland

- Joel Douglas
- Graeme Nimmo
- Claire Heney
- Narelle George
- Haakon Berg
- Elizabeth Catchpoole
- PA Laboratory

PAH

- Geoff Playford
- Naomi Runnegar
- Infection control team

RBWH

- Jeff Lipman
- Krispin Hajkowicz
- Marion Woods
- Trish Hurst
- Infection Control Team

Funding: RBWH ID Dept., PQ Study Education & Research Committee (SERC)

Transparency: No conflicts of interest to declare